GSK to buy food allergy drug maker RAPT in $2.2bn deal
US-based biotech firm is developing treatment for allergies to nuts, milk and eggs in children and adults
The Guardian - UK ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from RAPT
RAPT Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, RAPT Therapeutics (NASDAQ:RAPT) reported Q1 sales of $641.00 thousand. Earnings fell to a loss of $20.47 million, resulting in a 14.16% decrease from last quarter.
Benzinga ·
Really Rapt in Felt: Canberra fashion parade and online auction of original garments
If you can't make the parade, you can bid online for the fabulous fashion
The Canberra Times ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Read news from The Economist, FT, and more,
with one subscription
with one subscription
RAPT Therapeutics: Q4 Earnings Insights
RAPT Therapeutics (NASDAQ:RAPT) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Benzinga ·
Coverage From
Benzinga
The Canberra Times
The Guardian - UK
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
